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Background: Multiple sclerosis (MS) is the most common chronic autoimmune demyelinating 
and inflammatory disease of the central nervous system, afflicting both the body and mind. 
The risk of suffering from MS is 2.5–3.5 times greater in females than in males. While there 
is extant research on fatigue, depression, and cognitive impairment in patients with MS during 
its clinical course, there is a lack of research focusing on sleep, psychological functioning, and 
physical activity (PA) at the point of disease onset. The aims of the present study were therefore, 
to assess the markers of mental toughness (MT) as a dimension of psychological functioning, 
sleep disturbances (SD), and PA among patients at the moment of disease onset and to compare 
these with the corresponding values for healthy adolescents and young adults.
Methods: A total of 23 patients with MS at disease onset (mean age =32.31 years; 91% females), 
23 healthy adolescents (mean age =17.43 years; 82% females), and 25 healthy young adults 
(mean age =20.72 years; 80% females) took part in the study. They completed questionnaires 
covering sociodemographic data, MT, SD, and PA. 
Results: Patients with MS had similar scores for MT traits as those in healthy adolescents and 
healthy young adults, and equivalent levels of moderate-intensity PA and SD as young adults. 
MS patients reported lower levels of vigorous PA compared to both healthy adolescents and 
young adults. 
Conclusion: The pattern of the results of the present study suggests that the onset of MS is 
not associated with poor MT, poor sleep, or reduced moderate-intensity PA. Lower levels of 
vigorous PA were observed in MS patients. Low levels of vigorous PA may lead to decreased 
cardiorespiratory fitness in patients with MS and, in the long run, to reduced cardiovascular 
health and degraded psychological functioning.
Keywords: multiple sclerosis, illness onset, mental toughness, sleep disturbances, physical 
activity, healthy controls
Introduction
Neurodegenerative conditions such as dementia, Parkinson’s disease, Huntington’s 
disease (HD), and multiple sclerosis (MS) are often characterized by significant psycho-
logical and physical deficits such as sleep disturbance (SD) and low physical activities 
that interfere significantly with patients’ abilities and their overall quality of life.1–7 In 
this context, MS is the most common chronic autoimmune demyelinating and inflam-
matory disease of the central nervous system. Demyelination in association with axonal 
damage results in slowing of nerve signals, leading to typical MS symptoms such as 
feeling tired (fatigue), pain, visual problems, paresthesia, and problems of movement 
and balance.8 MS is associated with several comorbidities including an increase in 
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depressive symptoms, social withdrawal, reduced sexual drive, 
increased physical inactivity, and SD.9,10 Further, excessive 
fatigue severely reducing physical activity (PA) and exercising 
is experienced by at least two-thirds of MS patients.11
A broad range of medications is available to treat MS 
during the course of the disease.12–16 More specifically, the 
past two decades have witnessed remarkable advances in the 
treatment options for MS. New drugs have been developed 
on the basis of the knowledge of the pathobiology of MS,17 
and as for now, medical treatment is the first-line treatment 
for MS.12,14–16 Accordingly, several disease-modifying drugs 
including interferon beta 1a and 1b, glatiramer acetate, 
natalizumab, mitoxantrone, and fingolimod are licensed 
worldwide to reduce the frequency of clinical attacks with 
the hope of slowing disability progression.17–19 Fingolimod 
is a once-daily oral medication approved for relapsing MS.17 
Because interferon beta and glatiramer acetate have favorable 
long-term safety profiles and minimal monitoring require-
ments, they remain the common first-line choices despite 
competition from new oral therapies.17 Medication, though, 
was not the focus of concern in the present paper; instead, 
we examined psychological and sleep- and PA-related 
characteristics at illness onset.
Specifically, although research on the quality of life in 
MS patients has gained increasing interest, we decided to 
introduce a further psychological dimension, that is, we 
asked about patients’ mental toughness (MT). MT refers 
to an individual’s capacity to be consistently successful in 
coping with difficult life circumstances.20 Most studies in 
this field have focused on MT in elite athletes; these studies 
have shown that mentally tough athletes are able to cope with 
stress during a competition and to remain more focused and 
confident in the course of competition.20–23
Other studies have considered the association between 
MT and stress. For example, Gerber et al24,25 showed that 
adolescents with higher scores for MT were more resilient 
against stress. Accordingly, adolescents who were mentally 
tougher in a stressful situation were at a low risk of burnout 
compared to peers with lower scores for MT.26,27 The bot-
tom line appears to be that people with lower levels of MT 
experience greater stress when dealing with difficult and 
frustrating situations.
The concept of MT has been recognized recently for its 
psychological importance not just in coping with stress24 but 
also for its association with higher PA,28 and for its impact on 
both,29,30 and objective sleep quality.31 Consequently, there 
has been growing recognition of the applicability of MT to 
groups other than non-elite athletes, for example, healthy 
adolescents;29–31 healthy young adults;24 lower, middle, and 
senior managers; and clerical/administrative workers in 
early, middle, and late adulthood.32 However, to the best of 
our knowledge, MT traits have not so far been assessed in 
patients with MS, either at illness onset or during the course 
of the illness. Further aims of the present study were therefore 
to assess MT traits among patients with MS at disease onset 
and to compare the results from this group with those from 
healthy adolescents and young adults.
Overall, the concept of MT has been proven to be asso-
ciated with a broad variety of cognitive, emotional, and 
behavioral dimensions. We chose to examine MT in patients 
with MS for the following reasons: 1) MT consists of four 
key factors: control (of own life and emotions), commit-
ment, challenge, and confidence (in own abilities and in 
other people; Table 1), thus covering a range of cognitive–
emotional processes closely involved in coping with stress, 
emotions, unexpected events, and social settings (confidence 
in other people); 2) MT is related to subjective and objec-
tive sleep; 3) MT is related to PA; 4) MT has not previously 
been assessed in patients with MS; 5) MT offers an excel-
lent basis for both cross-sectional and longitudinal studies; 
6) MT reflects a trait rather than a state marker; and 7) given 
that the Mental Toughness Questionnaire 48 (MTQ48)20 
has been validated in different age and professional groups, 
data from previous studies (samples) are comparable with 
new samples.
We took all these considerations into account and asked 
about the MT profile of patients with MS at disease onset. 
Given that MT is considered a trait marker, we anticipated 
that scores would not differ from those of healthy controls 
immediately after a dramatic event such as the diagnosis 
of MS. Further, we applied MTQ48,20 thus allowing 
comparison with previous research.
A further core symptom of MS is fatigue, which means 
increased physical and psychological tiredness. Plausibly, 
fatigue might be associated with poor sleep though, 
surprisingly, the association between poor sleep and fatigue 
has been little studied so far. Only recently, Strober33 reviewed 
the state-of-the-art and concluded that the association between 
sleep and fatigue has been understudied and unrecognized, 
and that poor sleep is a significant contributor to fatigue. In the 
light of this observation, the first aim of the present study was 
to assess whether and to what extent SD might be precursors 
of MS at illness onset and to what extent any SD are compa-
rable to those of healthy adolescents and young adults.
With regard to PA, there are three principal reasons why 
patients with MS may be less active than healthy people:34,35 
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fatigue, impairment, and lack of time. Whereas lack of time 
seems to be a common reason for people not to exercise, 
impairment and fatigue are potentially MS specific.34–36 
With regard to impairment, there is some evidence of a 
negative feedback loop in that acute PA may lead to immedi-
ate impairment together with physical and mental discomfort. 
However, there is evidence that impairments and discomfort 
are due to an acute increase in body temperature and not to 
PA as such (Uhthoff’s phenomenon37). Further, the course 
of Huntington’s Disease, a neurodegenerative disorder, 
indicates that a less physically active lifestyle is a preclini-
cal predictor of earlier disease onset.38 Thus, although it is 
well established that patients with MS report reduced PA 
during the course of the disease, and although in the case 
of another neurodegenerative disorder we have learnt that a 
less active lifestyle is associated with earlier illness onset, 
to the best of our knowledge, the level of PA at illness onset 
among patients with MS has yet to be studied. Accordingly, 
the second aim of the present study was to assess levels of 
moderate and vigorous PA of patients with MS at disease 
onset and to compare these levels with those of healthy 
adolescents and young adults.
Additionally, previous studies have shown that patients 
with MS reported increased symptoms of depression and anxi-
ety during the course of the disease,5,39 while, more recently, the 
psychological dimension of quality of life has gained greater 
attention, thus shifting from a strictly psychiatric perspective 
to a more comprehensive psychological appraisal.40,41
To summarize, the aims of the present study were to 
explore to what extent psychological dimensions (here MT), 
sleep, and PA might be already affected at the onset of MS, 
thus providing indications of disease onset at psychological, 
sleep-related, and activity-related levels. To these ends, we 
assessed patients with MS at illness onset as well as healthy 
adolescents and healthy young adults. We believe that the 
pattern of results revealed in this study might be of practical 
importance, because until now, the only reliable state markers 
of the onset of MS were neurocognitive assessments to detect 
neurocognitive impairments42–45 and imaging techniques to 
assess cortical atrophy.46–50 These assessments, however, 
are time-consuming, expensive, require specialist expertise, 
and are not a part of annual routine medical checkups. By 
contrast, changes in sleep quality, PA, and cognitive, emo-
tional, and behavioral frameworks are more easily detected 
both by individuals affected by MS and by their close family 
members and friends. 
In the absence of existing evidence on patients with 
MS at illness onset, the following research questions were 
formulated in lieu of hypotheses: first, do the MT traits of 
patients with MS at illness onset differ significantly from 
Table 1 Descriptive and inferential statistical overview of mental toughness traits, sleep disturbances, and physical activity of patients 
with diagnosed Ms, healthy adolescents, and healthy young adults
Demographics, mental toughness, 
sleep disturbaces, and physical activity
Groups Statistics
MS HA HYAdu Factor group Post hoc tests
N 23 23 25
sex (female/male) 21/2 19/4 20/5 χ2(2) =1.39
Mean (SD) Mean (SD) Mean (SD) F
age (years) 32.31 (7.04) 17.43 (1.91) 20.72 (2.53) 72.15*** Ms . hYadu . ha
Mental toughness
challenge 26.47 (3.95) 28.27 (2.93) 31.60 (1.53) 18.85*** hYadu . Ms, ha
commitment 38.30 (5.78) 38.11 (3.11) 41.00 (2.75) 3.81* hYadu . ha
control emotion 21.47 (4.04) 20.52 (3.39) 21.52 (1.41) 0.77 –
control life 23.35 (4.66) 23.40 (1.80) 25.56 (2.29) 3.90* hYadu . ha
control total score 44.82 (7.28) 43.93 (3.42) 47.08 (2.45) 2.78* hYadu . ha
Confidence abilities 29.28 (5.33) 30.52 (4.17) 34.80 (2.36) 10.50*** hYadu . Ms, ha
Confidence interpersonal 20.78 (3.26) 21.66 (2.10) 21.92 (1.75) 1.41 –
Confidence total score 50.61 (5.93) 52.18 (5.01) 56.72 (1.81) 11.78*** hYadu . Ms, ha
Mental toughness total score 160.21 (19.86) 162.50 (5.94) 176.40 (3.86) 12.91*** hYadu . Ms, ha
Sleep disturbances 11.96 (4.99) 6.57 (1.90) 11.16 (1.95) 18.70*** ha , Ms, hYadu
Moderate physical activity  
(min/week)
505.65 (145.74) 251.30 (33.90) 416.96 (137.37) 3.71* Ms . ha
hYadu . ha
Vigorous physical activity (min/week) 164.13 (91.48) 409.48 (16.52) 466.48 (97.54) 19.64*** hYadu . ha . Ms
Notes: Degrees of freedom: always (2, 68); *P,0.05; ***P,0.001. Post hoc tests after Bonferroni–holm corrections for P-values: ,, less than/lower than; ., more than/
higher than.
Abbreviations: Ms, multiple sclerosis; ha, healthy adolescents; hYadu, healthy young adults; M, male; F, female.
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those of healthy adolescents or healthy young adults? Second, 
are patients with MS at illness onset more likely to report SD 
than healthy adolescents and healthy young adults? Third, 
do patients with MS at illness onset report less moderate 
or less vigorous PA than healthy adolescents and healthy 
young adults?
Methods
Procedure
Three different populations were assessed and compared in 
the present study: patients with MS at disease onset, healthy 
adolescents, and healthy young adults. All the participants 
were informed about the voluntary character of participation 
and assured that all the data were gathered anonymously. 
Written informed consent was obtained from the participants 
or from their legal representatives in case they were minors 
(,18 years). All the participants completed a series of ques-
tionnaires covering sociodemographic data, MT, SD, and 
PA (see “Materials” section). Completion of the question-
naire took 30–40 minutes. The local ethics committee of the 
University of Basel (Basel, Switzerland) approved the study, 
which was performed in accordance with the principles laid 
down in the Declaration of Helsinki. 
Samples
Patients with diagnosed Ms
A total of 23 patients with diagnosed MS (mean 
age =32.31 years; standard deviation =7.04; 91.3% females) 
took part in the study. A trained neurologist not otherwise 
involved in the study diagnosed the patients as having MS 
1–30 days before they were enrolled in the study. In other 
words, the diagnosis of MS was recent; these patients were 
new cases of MS. The patients completed the questionnaires 
individually during a routine checkup. A trained psychologist 
assisted the patients in case of questions.
healthy adolescents
Data from 23 adolescents (mean age =17.43 years; standard 
deviation =1.91; 82.61% females) were derived from a larger 
sample, as already described by Brand et al.28 The partici-
pants were young adolescents with regular schedules such 
as attending school fulltime, individual sports activities and 
leisure time activities such as playing music, attending music 
events, and similar. Of the total sample of 1,475 adolescents, 
data of 23 participants were randomly selected to build a 
subgroup for the present study (data set) and to present a 
representative of the pattern of results of the total sample (for 
more details, refer the study by Brand et al). The participants 
filled in the questionnaires during a regular school lesson.
healthy young adults
Data from 25 healthy young adults (mean age =20.72 years; 
standard deviation =2.53; 80% females) were derived from 
a larger sample, as already described in another study.24 The 
participants were young adult students from University of 
Basel (Switzerland), currently attending university classes 
fulltime. Of the total sample of 140 young adult students, 
the data of 25 participants were randomly selected to build 
a subgroup for the present study (data set) and to present a 
representative of the pattern of results for the sample as a 
whole. The participants completed the questionnaires during 
a regular lecture.
Materials
The participants completed a series of standardized question-
naires related to sociodemographic data, MT, SD, and PA. 
sociodemographic background
The participants reported their sex and age; additionally, 
patients with diagnosed MS reported time since onset of 
disease (in days).
Mental toughness
MT was assessed with MTQ48.20 It consists of 48 items, 
which are aggregated to the following dimensions: chal-
lenge (eg, “Challenges usually bring out the best in me”), 
commitment (eg, “I don’t usually give up under pressure”), 
emotional (eg, “Even when under considerable pressure 
I usually remain calm”) and life control (eg, “I generally 
feel in control”), interpersonal confidence (eg, “I usually 
take charge of a situation when I feel it is appropriate”), 
and confidence in ability (eg, “I am generally confident 
in my own abilities”). The factorial validity of MTQ48 
has been proved in previous studies.24,32 Further, MTQ48 
has a high test–retest reliability and a high internal con-
sistency. Items are anchored on 5-point Likert scales from 
1 (= strongly disagree) to 5 (= strongly agree), with higher 
scores reflecting greater MT. Additionally, responses 
across items were summed to obtain an overall MT index 
(Cronbach’s alpha =0.84–0.91). 
Physical activity
PA was assessed with the short version of the International 
Physical Activity Questionnaire (IPAQ). IPAQ was developed 
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by a working group initiated by the World Health Organization 
and the Centers for Disease Control and Prevention. Based 
on the results from 12 countries, reliability and validity of 
IPAQ were comparable to other self-reported measures 
of PA.51 The short form (self-administered, seven-item) 
of IPAQ was administered, asking about time spent in PA 
over the last 7 days. Minutes of sitting and walking as well 
as moderate-intensity (walking not included) and vigorous-
intensity activities were calculated for the past week. The 
IPAQ questionnaires (short and long versions), including 
definitions of moderate and vigorous activity, are available 
at http://www.ipaq.ki.se.
sleep disturbances
SD were assessed with the Insomnia Severity Index.52 This 
questionnaire is a seven-item screening measure for insom-
nia and an outcome measure for use in treatment research. 
The items, answered on 5-point rating scales ranging from 
0 (= not at all) to 4 (= very much), refer in part to the Diag-
nostic and Statistical Manual of Mental Disorders (Fourth 
Edition)53 criteria for insomnia by assessing difficulty falling 
asleep, difficulty remaining asleep, early morning awaken-
ings, impaired daytime performance, low satisfaction with 
sleep, and worry about sleep. The higher the overall score, 
the more the participant is assumed to suffer from insomnia 
(Cronbach’s alpha =0.87).
Statistical analysis
A chi-square test was performed to compare sex distribu-
tions between the three groups. Next, a series of univariate 
analysis of variance (ANOVA) was performed with group 
(MS patients, healthy adolescents, and healthy young adults) 
as an independent factor and age, MT, SD, and PA as depen-
dent variables. The nominal level of significance was set at 
alpha P,0.05. All statistical computations were performed 
with SPSS® 22.0 (IBM Corporation, Armonk NY, USA) for 
Apple Mac®.
Results
group differences in sociodemographic 
background
All descriptive and inferential statistical indices are reported 
in Table 1. Statistically significant group differences were 
found with regard to age, with MS patients having the 
highest age, followed by healthy young adults and healthy 
adolescents. Sex distribution did not differ between the three 
groups, P.0.05. 
group differences in MT and sD
With regard to MT, all descriptive and inferential statistics for 
patients with diagnosed MS, healthy adolescents, and healthy 
young adults are shown in Table 1. As can be seen from the 
ANOVAs, there were significant group effects for challenge, 
commitment, life control, confidence in own abilities, confi-
dence total score, and MTQ48 total score. A nonsignificant 
trend (P,0.1) was observed for control total score. Post hoc 
analyses after Bonferroni–Holm corrections for P-values 
showed that healthy young adults had significantly higher 
scores for challenge, confidence in own abilities, confidence 
total score, and MTQ48 total score, compared to patients with 
MS and healthy adolescents (Figure 1). No significant group 
differences were observed for control of emotions or interper-
sonal confidence. Of note, no significant mean differences were 
observed between healthy adolescents and patients with MS.
With regard to SD, there was a significant group effect 
(Table 1). Post hoc analyses after Bonferroni–Holm cor-
rection for P-values showed that healthy adolescents had 
the lowest level of SD, whereas SD did not differ between 
patients with MS and healthy young adults (Figure 2). 
group differences in Pa
Table 1 also reports all descriptive and inferential statistical 
indices related to PA. ANOVAs showed significant effects of 
group for both moderate and vigorous PA. Post hoc analyses 
after Bonferroni–Holm corrections for P-values showed 
that healthy young adults and healthy adolescents reported 
significantly higher levels of vigorous PA than patients 
with MS. Furthermore, healthy adolescents also reported 
more vigorous PA than healthy young adults (Figure 3). 
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Figure 1 Mental toughness.
Notes: Mental toughness differed significantly between the groups, with significantly 
higher mental toughness among hYadu, compared to patients with Ms and ha. 
Points are mean values, and bars are standard deviation. *Significant mean difference 
compared to other mean values.
Abbreviations: Ms, multiple sclerosis; ha, healthy adolescents; hYadu, healthy 
young adults.
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Finally, patients with MS and young adults reported higher 
levels of moderate PA than did healthy adolescents, whereas 
no significant differences were found between patients with 
MS and health young adults (Figure 4). 
Discussion
The key findings of the present study were that MT levels 
on all dimensions of patients with MS at illness onset were 
similar to those of healthy adolescents and healthy young 
adults; patients with MS also had equal amounts of moderate 
PA and degrees of SD as young adults. However, patients 
reported lower levels of vigorous PA than either healthy 
adolescents or young adults. The present pattern of results 
adds to the current literature in showing that patients with MS 
at illness onset did not differ from healthy adolescents and 
healthy young adults in MT traits, SD, or moderate PA. 
Three research questions were formulated and each of 
these is considered now in turn.
With the first research question, we focused on possible 
differences in MT traits between patients with MS at illness 
onset and healthy adolescents and young adults. The pattern 
of results in patients with MS showed a difference in overall 
MT score compared to healthy young adults, but not com-
pared to healthy adolescents. Further inspection (Table 1) 
revealed that patients with MS at illness onset did not differ 
statistically from healthy young adults with regard to com-
mitment, life control, emotion control, control overall score, 
or interpersonal confidence. Next, to further contextualize the 
present results, it should be noted that the sample of healthy 
young adults included sports students who, almost by defini-
tion, report higher levels of MT54 along with greater PA.
Overall, we believe that the present data add to the exist-
ing literature on MT in that this is the very first study on MT 
traits among patients with MS at illness onset. The study 
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Figure 2 sleep disturbances.
Notes: Sleep disturbances differed significantly between the groups, with significantly 
lower sleep disturbances among ha, compared to patients with Ms and hYadu. 
Points are mean values, and bars are standard deviation. *Significant mean difference 
compared to other mean values.
Abbreviations: Ms, multiple sclerosis; ha, healthy adolescents; hYadu, healthy 
young adults.
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Figure 3 Vigorous physical activity.
Notes: Vigorous physical activity differed significantly between the groups, with 
significantly higher vigorous physical activity among HYAdu compared to HA and 
patients with MS. Further, HA reported significantly more vigorous PA compared to 
patients with MS. Points are mean values, and bars are standard deviation; *significant 
mean difference compared to other mean values.
Abbreviations: Ms, multiple sclerosis; ha, healthy adolescents; hYadu, healthy 
young adults.








06 +$ +<$GX0R
GHU
DWH
SK\
VLFD
ODF
WLYLW
\P
LQZ
HHN

*URXSV

Figure 4 Moderate physical activity.
Notes: Moderate physical activity differed significantly between the groups, with 
significantly higher moderate physical activity among patients with MS compared to 
ha, and also higher moderate physical activity among hYadu compared to ha, but 
there was no significant difference between patients with MS and HYAdu. Points are 
mean values, and bars are standard deviation; *significant mean difference compared 
to other mean values.
Abbreviations: Ms, multiple sclerosis; ha, healthy adolescents; hYadu, healthy 
young adults.
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also adds to the current literature on MS in suggesting that at 
illness onset, MT levels of patients with MS are not different 
from those of healthy adolescents and young adults. Further 
and importantly, the present findings are at odds with those 
studies reporting increased symptoms of depression and 
anxiety5,39 and a lower quality of life.40,41
Our second research question concerned whether patients 
with MS at illness onset reported more SD than healthy 
adolescents or healthy young adults, and the answer was no. 
Therefore, again, we hold that the current pattern of results 
adds to the literature in showing that sleep at illness onset in 
patients with MS is not impaired compared to healthy young 
adults. Had this been the case, it then would have been pos-
sible that either alterations in the neuronal centers responsible 
for sleep-wake-generation and coordination55 or psychological 
issues (refer the study by Riemann et al56 for the hyperarousal 
model of SD) or both were responsible for poorer sleep. 
Further, the present results are at odds with those studies33,57,58 
reporting impaired sleep patterns in patients with MS.
Third, we asked whether patients with MS at illness onset 
would report lower moderate, or vigorous PA, as compared to 
healthy adolescents and healthy young adults, and the answer 
was no. Specifically, they reported higher levels of moderate 
PA than healthy adolescents, and, descriptively, than healthy 
young adults, though these patients also reported lower levels 
of vigorous activity. Again, we hold that the present pattern 
of results adds to the current literature in showing that, at 
illness onset, PA does not appear to be impaired or reduced 
in patients with MS. Likewise, and in contrast to the findings 
from patients with Huntington’s Disease,38 PA patterns are 
not good predictors of preclinical symptoms. Further, the 
present pattern of results is at odds with those studies showing 
a decrease in PA among patients with MS.1,34,35
The novelty of the results should be balanced against the 
limitations of the study, which preclude overgeneralization 
of the findings. First, the sample sizes were small, though 
statistically significant mean differences were observed. 
Second, female participants predominated in the samples, 
though we note that females have a 2.5–3.5 times greater risk 
of suffering from MS than males. Third, no objective data 
were collected; objective assessments of PA and objective 
sleep measures, for example, would have provided a more 
complete picture and more reliable data on both PA and sleep. 
Fourth, it would have been interesting and enlightening to 
compare the present data with neurocognitive performance 
and imaging data in order to determine to what extent MT 
traits, SD, and PA are associated with neuronal changes and 
cognitive performance. Fifth, the present pattern of results 
might have emerged due to further latent but unassessed 
dimensions, which might have biased two or more dimen-
sions in similar or opposite directions. Sixth, it would have 
been interesting to assess daytime sleepiness and fatigue, 
and to relate these to SD. This would have allowed a more 
thorough investigation of the association between poor 
sleep, tiredness, and fatigue, given that up to now there 
has been so little research on these associations. Seventh, 
it might be arguable to what extent it was useful to com-
pare data of patients with MS at disease onset with data of 
healthy adolescents and healthy young adults (students in 
sport science). However, we followed Roberts et al,59 who 
showed a continuity of personality growth toward greater 
maturity from adolescence to young adulthood. Therefore, 
we wanted to explore to what extent continuity and change 
in personality would have been reflected in MT traits among 
these three different samples. In this view, the present data 
showed that such comparisons were reasonable, as patients 
with MS at disease onset reported very similar traits as did 
the healthy adolescents and healthy young adults. Eighth, 
the topic of MT gets increasingly assessed among nonelite 
athletes such as lower, middle, and senior managers, and 
clerical/administrative workers in early, middle, and later 
adulthood.32 Accordingly, we consider the present study 
as a contribution to the research on MT as a general set of 
personality traits covering dimensions such as stress man-
agement, self-esteem, confidence in social environment, and 
coping with changes. Lastly, the cross-sectional character of 
the study does not shed any light on the illness course; in this 
regard, it would be intriguing to know whether MT traits, 
SD, or amount of PA predict the future course of the illness 
along with quality of life.
Conclusion
The pattern of results suggests that patients with MS at illness 
onset show patterns of MT traits, SD, and PA comparable to 
those of healthy adolescents and young adults. We believe 
that the therapeutic challenge is to keep these features stable 
over the course of treatment and illness.
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